JLE

Hépato-Gastro & Oncologie Digestive

MENU

Réactivation de l’infection par le virus de l’hépatite B par le traitement de l’hépatite C avec les nouveaux antiviraux directs Volume 25, numéro 1, Janvier 2018

  • [1] Pol S., Haour G., Fontaine H. The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. Aliment Pharmacol Ther. 2017;46:1054-1060.
  • [2] Chen G., Wang C., Chen J. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology. 2017;66:13-26.
  • [3] https://www.fda.gov/Drugs/DrugSafety/ucm522932.htm.
  • [4] http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/12/news_detail_002659.jsp&mid=WC0b01ac058004d5c1.
  • [5] Sato S., Fujiyama S., Tanaka M. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol. 1994;21:159-166.
  • [6] Perillo R.P. Hepatitis B reactivation during direct-acting antiviral treatment of chronic hepatitis C : a hidden danger of an otherwise major success story. Hepatology. 2017;66:4-6.
  • [7] AASLD Clinical Guidelines. https://www.hcvguidelines.org/evaluate/monitoring AASLD Clinical Guidelines.
  • [8] Recommandations AFEF sur la prise en charge de l’hépatite virale C - Mars 2017. http://www.afef.asso.fr/RECOMMANDATIONS/recommandations_1.